BFRA News and Press, Biofrontera AG From 04/13/21

Biofrontera AG (BFRA) Q4 2020 Earnings Conference Call April 13, 2021 08:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Ludwig Lutter - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Compa...

Biofrontera (BFRA): Q4 net loss of €1.06M.Revenue of €9.52M (-22.0% Y/Y)Press Release For further details see: Biofrontera reports Q4 results

Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the sam...

Biofrontera ([[BFRA]] -2.9%) reported 1Q21 preliminary revenue of ~ €5.6M a decline of 14% Y/Y.Revenues from product sales in the US were around ~€3.9M (-6% Y/Y); Germany, revenues from product sales amounted to ~€1.4M (+7% Y/Y); and in the rest of Europe, Company generat...

Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021. The Company...

Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the fiscal year 2020 on Monday, April 12, 2021. ...

Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for...

Gainers: Humanigen HGEN +98%, Universe Pharmaceuticals (UPC) +82%, EDAP (EDAP) +13%, Biofrontera (BFRA) +13%, Virpax Pharmaceuticals (VRPX) +7%.Losers: Millendo Therapeutics MLND -34%, Orphazyme (ORPH) -32%, Celldex Therapeutics CLDX ...

Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, announces the closing of the capital increase resolved by the ann...

Biofrontera ([[BFRA]] -8.5%) prices U.S. underwritten public offering of 1,334,002 ADSs, at an offering price of $6.68/ADS; company expects to receive aggregate gross proceeds of ~$8.9M.Proceeds to be used to conduct clinical studies aimed at improving the market positioning of Biofrontera&#x...